Atlas Trials

Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer

Clinical trial NCT06548919 · RECRUITING

Trial details

NCT number
NCT06548919
Sponsor
SciClone Pharmaceuticals
Status
RECRUITING
Study type
OBSERVATIONAL
ESR1 Gene MutationAdvanced Breast Cancer
Start date
2024-08-08
Primary completion
2026-12-31
Enrollment
450

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.